Publications by authors named "Steven Whittaker"

33Publications

Inactivation of Promotes Resistance to EGFR Inhibition in -Wild-Type Colorectal Cancer.

Mol Cancer Res 2020 06 25;18(6):835-846. Epub 2020 Feb 25.

Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.

View Article and Find Full Text PDF
June 2020

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.

Br J Cancer 2020 01 10;122(1):72-81. Epub 2019 Dec 10.

Cancer Research UK Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust, London, SM2 5PT, UK.

View Article and Find Full Text PDF
January 2020

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Pharmacol Ther 2017 May 5;173:83-105. Epub 2017 Feb 5.

Division of Cancer Therapeutics, The Institute of Cancer Research, London SW7 3RP, United Kingdom; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, United Kingdom. Electronic address:

View Article and Find Full Text PDF
May 2017

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.

Mol Cancer Ther 2015 Dec 8;14(12):2700-11. Epub 2015 Sep 8.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. The Broad Institute, Cambridge, Massachusetts. Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF
December 2015

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

Cancer Discov 2014 Jan 21;4(1):94-109. Epub 2013 Nov 21.

1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School; 2Department of Pathology, Massachusetts General Hospital Cancer Center, Boston; 3Broad Institute of MIT and Harvard; 4Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts; 5Department of Dermatology, University Hospital, West German Cancer Center, University Duisburg-Essen, Essen; 6German Cancer Consortium (DKTK); 7Department of Dermatology, Heidelberg University Hospital, Heidelberg; 8Department of Dermatology and Allergy, Hannover Medical School, Hannover; 9Department of Dermatology, University of Wuerzburg, Wuerzburg; 10Department of Dermatology, Venerology and Allergology, University of Schleswig-Holstein Hospital, Kiel; 11Department of Dermatology and Allergology, Ludwig-Maximilian University, Munich; 12Department of Dermatology, Venerology and Allergy, Charité Universitätsmedizin Berlin, Humboldt University, Berlin; 13Department of Dermatology, University of Mainz, Mainz; 14University Medical Center, University of Tübingen, Tübingen, Germany; 15Department of Genome Sciences, University of Washington, Seattle, Washington; 16Department of Dermatology, University Hospital Zurich, Zurich, Switzerland; and 17First Department of Medicine, Medical School, University of Athens, Athens, Greece.

View Article and Find Full Text PDF
January 2014

Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.

Bioorg Med Chem 2013 Mar 3;21(5):1284-304. Epub 2013 Jan 3.

The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF
March 2013

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Cancer Discov 2013 Mar 3;3(3):350-62. Epub 2013 Jan 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article and Find Full Text PDF
March 2013

A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.

Cancer Res 2010 Oct 31;70(20):8036-44. Epub 2010 Aug 31.

Signal Transduction Team, Section of Cell and Molecular Biology, Molecular Pathology Team, The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom.

View Article and Find Full Text PDF
October 2010

All roads lead to the ribosome.

Cancer Cell 2010 Jul;18(1):5-6

Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

View Article and Find Full Text PDF
July 2010

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Cell 2010 Jan;140(2):209-21

The Institute of Cancer Research, Signal Transduction Team, Section of Cell and Molecular Biology, 237 Fulham Road, London SW3 6JB, UK.

View Article and Find Full Text PDF
January 2010

The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis.

Cell Cycle 2007 Dec 5;6(24):3114-31. Epub 2007 Oct 5.

Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, UK.

View Article and Find Full Text PDF
December 2007

The EGF receptor Hokey-Cokey.

Cancer Cell 2007 Mar;11(3):209-11

The Institute of Cancer Research, Gene and Oncogene Targeting Team, Cancer Research UK Centre for Cancer Therapeutics, Sutton, Surrey SM2 5NG, UK.

View Article and Find Full Text PDF
March 2007

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.

J Med Chem 2006 Jan;49(1):407-16

Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF
January 2006

Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen.

J Biomol Screen 2006 Mar 16;11(2):145-54. Epub 2005 Dec 16.

Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, Sutton, UK.

View Article and Find Full Text PDF
March 2006

The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.

Cancer Res 2004 Jan;64(1):262-72

Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, United Kingdom.

View Article and Find Full Text PDF
January 2004